Pharmaceuticals

Kcentra Market 2026 growing with coagulation therapies

March 29, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Forecasted Market Value Of The Kcentra Market Across 2026–2030?

Historically, the growth stemmed from widespread warfarin use, a high bleeding risk in anticoagulated patients, early adoption of pcc products, emergency department demand, and hospital surgical safety needs.

The projected growth during the forecast period is primarily driven by an increasing elderly demographic utilizing anticoagulants, an escalation in emergency surgical procedures, heightened recognition of the advantages of PCC, the proliferation of trauma care facilities, and an expansion in the number of outpatient surgical interventions.

Significant developments expected throughout the forecast period involve an escalating need for prompt anticoagulation reversal, an increase in emergency hemostasis management, the broadening of surgical bleeding control therapies, more widespread application in trauma and critical care environments, and the reinforcement of hospital-based coagulation protocols.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20122&type=smp

Which Market Drivers Are Supporting The Expansion Of The Kcentra Market?

The Kcentra market is projected to expand due to the increasing incidence of bleeding disorders. These conditions, which include hemophilia, von Willebrand disease (VWD), and acquired coagulopathies, hinder the blood’s clotting ability, resulting in extended or severe bleeding. The growth in the prevalence of these disorders stems from genetic predispositions, advancements in diagnostic techniques, and heightened public awareness, which collectively lead to more effective global case detection. Kcentra, a prothrombin complex concentrate, serves as a treatment for bleeding disorders, notably in patients experiencing bleeding linked to vitamin K antagonists or warfarin. An illustration of this trend is found in data from December 2023 by the World Federation of Hemophilia, a Canada-based international nonprofit organization. Their World Bleeding Disorders Registry documented 13,343 individuals with hemophilia across 119 treatment centers in 44 countries in 2023, an increase from 12,296 individuals across 108 centers in 42 countries in 2022. Consequently, the rising occurrence of bleeding disorders fuels the Kcentra market.

What Segmentation Levels Are Considered In The Kcentra Market?

The kcentra market covered in this report is segmented –

1) By Indication: Urgent Reversal Of Warfarin Therapy, Treatment Of Acquired Coagulation Factor Deficiency, Management Of Major Bleeding Events

2) By Formulation: Injectable Formulation, Lyophilized Powder For Reconstitution

3) By Patient Demographics: Pediatric Patients, Adult Patients, Geriatric Patients

4) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies

5) By End User: Hospitals, Outpatient Surgical Centers, Emergency Departments, Specialty Clinics

What Trends Are Projected To Affect The Kcentra Market?

A significant trend evident in the kcentra market is the authorization of novel treatments, such as balfaxar (human prothrombin complex concentrate), which is fostering competitive advancements within the sector. Balfaxar is a therapy specifically formulated for the immediate reversal of acquired coagulation factor deficiency induced by warfarin therapy in adult patients needing urgent surgery or invasive procedures. Illustratively, in July 2023, Octapharma USA, a pharmaceutical company based in the U.S., declared that Balfaxar (prothrombin complex concentrate, human-lens, also known as octaplex in Europe and Canada) obtained approval from the U.S. Food and Drug Administration (FDA) for the emergency reversal of acquired coagulation factor deficiency caused by vitamin K antagonist (VKA, like warfarin) therapy in adult patients who require urgent surgery or invasive procedures. Balfaxar functions by re-establishing blood coagulation through the replenishment of the clotting factors made deficient by warfarin therapy.

Which Leading Firms Are Contributing To The Growth Of The Kcentra Market?

Major companies operating in the kcentra market are CSL Behring

Read the full kcentra market report here:

https://www.thebusinessresearchcompany.com/report/kcentra-global-market-report

How Is The Kcentra Market Distributed Across Key Geographic Regions?

North America was the largest region in the kcentra market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kcentra market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Kcentra Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20122&type=smp

Browse Through More Reports Similar to the Global Kcentra Market 2026, By The Business Research Company

Inductor Market Market Report 2026

https://www.thebusinessresearchcompany.com/report/inductor-market-global-market-report

Potassium Iodide Market Report 2026

https://www.thebusinessresearchcompany.com/report/potassium-iodide-global-market-report

Automotive Silicone Market Report 2026

https://www.thebusinessresearchcompany.com/report/automotive-silicone-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795